Prognostic Factors Influencing the Efficacy of Regorafenib in the Treatment of Metastatic Colorectal Cancer
Aim: Metastatic colorectal cancer (mCRC) remains a significant clinical challenge for patients who have exhausted standard treatment options. Regorafenib, an oral multikinase inhibitor, is approved for use in refractory with mCRC patients; however, its real-world efficacy continues to be an area of...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Tekirdağ Namık Kemal University
2025-06-01
|
| Серія: | Namık Kemal Tıp Dergisi |
| Предмети: | |
| Онлайн доступ: | https://namikkemalmedj.com/articles/prognostic-factors-influencing-the-efficacy-of-regorafenib-in-the-treatment-of-metastatic-colorectal-cancer/doi/nkmj.galenos.2025.34654 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|